MYH9 Antibody

What is MYH9 and why is it significant in cellular research?

MYH9 encodes the heavy chain of non-muscle myosin IIA (NMHC IIA), a critical component of the actin cytoskeleton that plays essential roles in various cellular processes. The gene is located on chromosome 22q12.3 and spans approximately 106 kilobases, containing 41 exons that translate into a protein of 1,960 amino acids. This protein functions as part of a hexameric complex that includes two heavy chains, two regulatory light chains, and two essential light chains . The MYH9 protein (also known as myosin-9) has a molecular weight of approximately 226.5 kilodaltons and interacts with actin filaments to facilitate crucial cellular activities including cell migration, adhesion, division, and maintenance of cell shape . Its importance in research stems from its fundamental role in cytoskeletal dynamics and its association with several inherited disorders when mutated.

What applications are most effective when working with MYH9 antibodies?

Based on comprehensive antibody validation data, MYH9 antibodies demonstrate utility across multiple applications with varying effectiveness:

When selecting an application, researchers should prioritize antibodies specifically validated for their intended use, as reactivity can vary significantly between applications . Additionally, confirming species cross-reactivity is essential as many antibodies show specificity for human, mouse, and rat orthologs, while others may recognize canine, porcine, or monkey variants .

How should researchers optimize sample preparation for MYH9 antibody experiments?

Sample preparation significantly impacts MYH9 antibody performance across applications. For Western blotting, complete lysis buffers containing protease inhibitors are essential due to MYH9's susceptibility to proteolytic degradation. When preparing samples:

• Use cell lysis buffers containing 1% NP-40 or RIPA buffer supplemented with fresh protease inhibitor cocktail

• For blood samples, implement specialized platelet isolation protocols that preserve large platelets (macrothrombocytes) which may be missed in standard isolation procedures

• For immunofluorescence, 4% paraformaldehyde fixation for 15-20 minutes followed by 0.1% Triton X-100 permeabilization has shown optimal results for preserving MYH9 structure

• For neutrophil analysis in MYH9-RD diagnostics, May-Grünwald-Giemsa (MGG) staining is recommended to identify Döhle-like inclusion bodies, although immunofluorescence detection of NMMHC-IIA aggregates offers superior sensitivity

Importantly, when working with platelets, standard automated counting methods may underestimate platelet counts in MYH9-RD due to the abnormal size of macrothrombocytes, necessitating careful assessment through specialized methods .

How can researchers differentiate between MYH9 and other non-muscle myosin heavy chain isoforms?

Differentiating between MYH9 (myosin IIA) and other non-muscle myosin heavy chains such as MYH10 (myosin IIB) and MYH14 (myosin IIC) requires strategic antibody selection and experimental design. High-specificity antibodies that target unique epitopes in the tail region of MYH9 show minimal cross-reactivity with other isoforms. For example, antibodies recognizing the C-terminal region of MYH9 typically show higher specificity, as noted with certain commercial antibodies like the polyclonal antibody PA5-17025, which is not cross-reactive with the non-muscle heavy chains of myosin IIB or IIC .

For experimental validation of specificity:

• Always include positive controls from tissues known to express predominantly MYH9 (such as platelets)

• Implement siRNA knockdown of MYH9 specifically to confirm antibody specificity

• Consider using multiple antibodies targeting different epitopes and comparing results

• In co-expression systems, employ dual immunofluorescence with differentially labeled antibodies to distinguish localization patterns

• Validate critical findings with mass spectrometry-based approaches to confirm protein identity

In cases requiring absolute specificity, researchers should consider combining antibody-based detection with molecular techniques targeting the specific nucleotide sequences unique to each isoform.

What methodologies are most effective for studying MYH9 in the context of hematopoiesis?

MYH9 plays a crucial role in hematopoiesis, particularly in the survival and maintenance of hematopoietic stem and progenitor cells (HSPCs). Loss of MYH9 function disrupts normal hematopoiesis, leading to severe blood cell deficiencies and bone marrow failure . When studying MYH9 in hematopoiesis contexts, researchers should implement a multi-faceted approach:

• Flow cytometry with MYH9 antibodies: Enables quantification of MYH9 expression levels across different hematopoietic lineages and developmental stages. Select antibodies specifically validated for flow cytometry applications, such as those designated for FCM in supplier catalogs .

• Colony formation assays: Combined with MYH9 knockdown or overexpression models to assess functional impact on progenitor cell differentiation.

• Lineage tracing studies: Using MYH9 expression as a marker to track cell fate decisions in hematopoietic development.

• Confocal microscopy with co-staining approaches: To visualize MYH9 localization during critical stages of megakaryocyte maturation and platelet formation.

• In vivo models: Conditional knockout models targeting MYH9 expression in specific hematopoietic lineages can reveal stage-specific requirements.

These methodologies are particularly valuable when investigating the role of MYH9 in megakaryopoiesis and thrombopoiesis, processes frequently disrupted in MYH9-related disorders.

How can researchers effectively utilize high-throughput sequencing alongside antibody-based approaches for MYH9-RD diagnosis?

High-throughput sequencing (HTS) has emerged as a powerful complement to antibody-based techniques for comprehensive diagnosis of MYH9-related disorders. The strategic integration of both approaches maximizes diagnostic accuracy and research insights:

• Initial antibody-based screening: Immunofluorescence detection of NMMHC-IIA aggregates in neutrophils offers high sensitivity for suspected MYH9-RD cases . This approach provides rapid initial assessment but may not be available in all diagnostic laboratories.

• Targeted HTS panel implementation: For cases with clinical suspicion of MYH9-RD, particularly those with macrothrombocytopenia, a targeted HTS approach focusing on bleeding and platelet disorder (BPD) genes has proven instrumental in reaching conclusive diagnoses, with studies showing HTS was decisive in diagnosing 46% of MYH9-RD patients .

• Variant confirmation protocol: Following HTS identification of MYH9 variants, researchers should:

  • Classify variants according to ACMG guidelines

  • Confirm pathogenicity through functional studies using domain-specific antibodies

  • Assess protein expression and localization patterns through immunofluorescence

  • Correlate genetic findings with neutrophil inclusion patterns detected by antibody staining

• Phenotype-genotype correlation analysis: Comprehensive diagnosis should integrate:

  • Clinical manifestations

  • Laboratory findings (including antibody-based detection of inclusion bodies)

  • Genetic variants identified through HTS

  • Family history and segregation analysis

Studies have demonstrated that this integrated approach substantially improves diagnostic yield, particularly in cases with atypical presentations where antibody-based methods alone might be inconclusive .

What are the critical considerations for Western blot analysis with MYH9 antibodies?

Western blot detection of MYH9 presents several technical challenges due to the protein's high molecular weight (~226.5 kDa) and structural complexity. Researchers should implement the following protocol modifications for optimal results:

• Gel selection and preparation:

  • Use low percentage (6-8%) polyacrylamide gels to facilitate migration of high molecular weight proteins

  • Consider gradient gels (4-15%) for improved resolution

  • Extend running time at lower voltage (80-100V) to prevent protein degradation during electrophoresis

• Transfer optimization:

  • Implement wet transfer systems rather than semi-dry methods

  • Use reduced methanol concentration (10% instead of typical 20%) in transfer buffer

  • Extend transfer time to 2-3 hours at constant amperage (or overnight at low voltage)

  • Consider adding SDS (0.1%) to transfer buffer to facilitate movement of large proteins

• Antibody selection and validation:

  • Prioritize antibodies with demonstrated Western blot application validation

  • Confirm epitope location (N-terminal vs. C-terminal regions may yield different results)

  • Verify species reactivity matches experimental samples

• Typical troubleshooting scenarios:

• Controls:

  • Always include positive control lysates from tissues known to express high levels of MYH9 (platelets, leukocytes)

  • Consider using recombinant MYH9 protein standards for size verification

  • Include loading controls appropriate for high molecular weight comparisons

These methodological refinements significantly improve detection sensitivity and specificity when working with MYH9 antibodies in Western blot applications.

How can researchers optimize immunofluorescence protocols for studying MYH9 localization?

Successful visualization of MYH9 localization through immunofluorescence requires careful optimization of multiple parameters to preserve structural integrity while ensuring antibody accessibility. The following methodology has been demonstrated to yield consistent results:

• Sample preparation optimization:

  • For adherent cells: Grow on glass coverslips coated with appropriate substrate (collagen, fibronectin) depending on cell type

  • For suspension cells (especially platelets/leukocytes): Use cytospin preparations or poly-L-lysine coated slides to ensure adhesion

• Fixation protocol comparison:

• Blocking optimization:

  • 5% normal serum (matched to secondary antibody species)

  • Addition of 0.1% Triton X-100 enhances penetration

  • Consider specialized blocking for phalloidin co-staining (if visualizing actin/MYH9 interactions)

• Primary antibody selection:

  • Prioritize antibodies validated specifically for IF/ICC applications

  • Dilution optimization critical (typically 1:100-1:500 range)

  • Incubation at 4°C overnight often yields better signal-to-noise ratio than room temperature incubations

• Visualization enhancements:

  • Counterstain with phalloidin conjugates to visualize actin/MYH9 interactions

  • Nuclear counterstaining with DAPI provides spatial context

  • In neutrophils studying MYH9-RD, specific immunofluorescence patterns detecting NMMHC-IIA aggregates show higher sensitivity than traditional MGG staining

• Advanced applications:

  • Super-resolution microscopy techniques (STORM, STED) can resolve detailed MYH9 filament structures

  • Live-cell imaging using fluorescently tagged MYH9 constructs complements fixed-cell antibody approaches

These methodological refinements significantly enhance the ability to accurately visualize MYH9 distribution and cytoskeletal interactions across diverse experimental contexts.

What strategies can resolve common issues when using MYH9 antibodies for studying MYH9-related disorders?

Researchers investigating MYH9-related disorders face several methodological challenges that require strategic approaches for successful experimental outcomes:

• Difficulty in accurate platelet counting:

  • Standard automated counters frequently underestimate platelet counts in MYH9-RD due to the abnormal size of macrothrombocytes

  • Solution: Implement manual counting methods or specialized automated systems calibrated for large platelets; combine with peripheral blood smear examination

• Variable detection of Döhle-like inclusion bodies:

  • Traditional May-Grünwald-Giemsa (MGG) staining may yield inconsistent results

  • Solution: Implement immunofluorescence techniques for detecting NMMHC-IIA aggregates, which offer superior sensitivity for diagnosis

• Challenges in genotype-phenotype correlation:

  • Heterogeneity in syndromic manifestations complicates interpretation of experimental findings

  • Solution: Integrate clinical data, laboratory findings, and genetic analysis using high-throughput sequencing (HTS) for comprehensive assessment

• Antibody specificity concerns:

  • Cross-reactivity with other non-muscle myosin heavy chains can confound results

  • Solution: Select antibodies specifically validated as non-cross-reactive with myosin IIB or IIC, such as certain polyclonal antibodies ; validate with knockout/knockdown controls

• Variability in mutation detection:

  • Different mutations in MYH9 may affect antibody binding differentially

  • Solution: Use multiple antibodies targeting different epitopes; combine antibody-based detection with HTS techniques for mutation identification

• Sample quality issues from rare patient populations:

  • Limited availability of well-characterized patient samples

  • Solution: Establish collaborative networks; implement cryopreservation protocols optimized to maintain MYH9 integrity; consider patient-derived iPSC approaches

By implementing these methodological refinements, researchers can overcome common technical challenges associated with studying MYH9-related disorders, leading to more robust and reproducible experimental outcomes.

How can emerging technologies enhance MYH9 antibody applications in research?

Emerging technologies are expanding the capabilities of MYH9 antibody applications in several promising directions:

• Single-cell proteomics integration:

  • Combining flow cytometry with mass cytometry (CyTOF) approaches allows simultaneous detection of MYH9 expression alongside dozens of other proteins at single-cell resolution

  • Application: Particularly valuable for characterizing heterogeneous responses in hematopoietic populations and identifying rare cellular subsets with altered MYH9 expression

• Proximity labeling approaches:

  • BioID or APEX2 fusion proteins with MYH9 enable identification of proximal interacting partners in living cells

  • Application: Discovering novel context-specific interactions in different cellular compartments and under various stimulation conditions

• Super-resolution microscopy optimization:

  • STORM, STED, and expansion microscopy techniques can now resolve MYH9 filament organization at nanometer resolution

  • Application: Detailed analysis of cytoskeletal reorganization during cellular processes like migration and division

• Liquid biopsy applications:

  • Development of highly sensitive detection methods for circulating MYH9 protein or associated biomarkers

  • Application: Potential for minimally invasive monitoring of MYH9-RD progression and treatment response

• CRISPR-based screening platforms:

  • Combination of CRISPR screening with MYH9 antibody-based detection methods

  • Application: Systematic identification of genetic modifiers affecting MYH9 expression, localization, and function

These technological advances significantly expand the experimental toolkit available for researchers investigating MYH9 biology and pathology, enabling more sophisticated analyses of this critical cytoskeletal component.

What are the most promising therapeutic targets being investigated for MYH9-related disorders?

Recent research on MYH9-related disorders has identified several promising therapeutic strategies targeting different aspects of disease pathophysiology:

• Myosin activity modulators:

  • Small molecules targeting myosin ATPase activity show potential for modulating MYH9 function

  • Mechanistic approach: Fine-tuning of contractile properties rather than complete inhibition

  • Research stage: Preclinical studies demonstrating proof-of-concept in cellular and animal models

• Thrombopoietin receptor agonists:

  • Eltrombopag and romiplostim show therapeutic potential for the thrombocytopenia component of MYH9-RD

  • Mechanistic approach: Stimulation of platelet production to compensate for abnormal platelet clearance

  • Research stage: Case reports and small series showing efficacy in selected patients

• Gene therapy approaches:

  • AAV-mediated delivery of functional MYH9 to affected tissues

  • CRISPR-based correction of pathogenic variants

  • Research stage: Early preclinical development with proof-of-concept in cellular models

• Protein stabilization strategies:

  • Chemical chaperones and proteostasis modulators to enhance folding of mutant MYH9 proteins

  • Mechanistic approach: Preventing aggregation and improving functional protein levels

  • Research stage: High-throughput screening of compound libraries identifying lead candidates

• Targeted prevention of end-organ damage:

  • ACE inhibitors/ARBs for nephroprotection in patients with MYH9 mutations

  • Cochlear protection strategies for hearing loss prevention

  • Research stage: Observational studies suggesting benefit; controlled trials needed

These emerging therapeutic approaches represent diverse strategies for addressing the complex multisystem pathology of MYH9-related disorders, with several approaches showing promise for translation to clinical applications.